Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 17/20 | 0.69 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.69 |
| ▸ | OGA | O60502 | 1/20 | 0.50 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1823513 | 0.90 | HRH4 (0.67) | HRH4HRH3OGAACHEBACE1 | |
| SCHEMBL1823511 | 0.90 | HRH4 (0.67) | HRH4HRH3OGAACHEBACE1 | |
| SCHEMBL604034 | 0.90 | HRH4 (0.70) | HRH4HRH3OGA | |
| SCHEMBL604033 | 0.90 | HRH4 (0.70) | HRH4HRH3OGA | |
| SCHEMBL846870 | 0.90 | HRH4 (0.70) | HRH4HRH3OGA | |
| SCHEMBL1589627 | 0.88 | HRH4 (0.65) | HRH4HRH3OGAALKACHE | |
| SCHEMBL846822 | 0.85 | HRH4 (0.68) | HRH4HRH3OGAALKACHE | |
| SCHEMBL605842 | 0.83 | HRH4 (0.73) | HRH4HRH3 | |
| SCHEMBL605841 | 0.83 | HRH4 (0.73) | HRH4HRH3 | |
| SCHEMBL1825607 | 0.82 | HRH4 (0.73) | HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732087-B2 | Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2017-08-15 | — | — | US | claimed |
| US-20140357614-A1 | Diamino-Pyridine, Pyrimidine, and Pyrazine Modulators of the Histamine H4 Receptor | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-04 | — | — | US | claimed |
| JP-2011524363-A | — | — | 2011-09-01 | — | — | JP | claimed |
| CN-102118969-A | Histamine H4Diaminopyridine, diaminopyrimidine, and diaminopyridazine modulators of receptors | JANSSEN PHARMACEUTICA NV | 2011-07-06 | — | — | CN | claimed |
| EP-2315521-A1 | DIAMINO-PYRIDINE, PYRIMIDINE, AND PYRIDAZINE MODULATORS OF THE HISTAMINE H 4 RECEPTOR | Janssen Pharmaceutica NV (BE) | 2011-05-04 | — | — | EP | claimed |
| US-20110092474-A1 | Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV | 2011-04-21 | — | — | US | claimed |
| WO-2009152325-A1 | DIAMINO-PYRIDINE, PYRIMIDINE, AND PYRIDAZINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-17 | — | — | WO | claimed |
| US-20170298022-A1 | Diamino-Pyridine, Pyrimidine, and Pyridazine Modulators of the Histamine H4 Receptor | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-19 | — | — | US | disclosed |
| US-20170298022-A1 | Diamino-Pyridine, Pyrimidine, and Pyridazine Modulators of the Histamine H4 Receptor | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-19 | — | — | US | disclosed |
| US-9732087-B2 | Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2017-08-15 | — | — | US | disclosed |
| US-9732087-B2 | Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2017-08-15 | — | — | US | disclosed |
| US-9732087-B2 | Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2017-08-15 | — | — | US | disclosed |
| US-20140357614-A1 | Diamino-Pyridine, Pyrimidine, and Pyrazine Modulators of the Histamine H4 Receptor | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-04 | — | — | US | disclosed |
| US-8841287-B2 | Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-09-23 | — | — | US | disclosed |
| US-8841287-B2 | Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-09-23 | — | — | US | disclosed |
| EP-2315521-B1 | DIAMINO-PYRIDINE, PYRIMIDINE, AND PYRIDAZINE MODULATORS OF THE HISTAMINE H 4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-21 | — | — | EP | disclosed |
| US-20110092474-A1 | Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV | 2011-04-21 | — | — | US | disclosed |
| US-20110092474-A1 | Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV | 2011-04-21 | — | — | US | disclosed |
| US-20110092474-A1 | Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV | 2011-04-21 | — | — | US | disclosed |
| WO-2009152325-A1 | DIAMINO-PYRIDINE, PYRIMIDINE, AND PYRIDAZINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298022-A1 | Diamino-Pyridine, Pyrimidine, and Pyridazine Modulators of the Histamine H4 Receptor | HRH4, HRH3, HRH1 | HRH4 1/4885HRH3 2/4885OGA 4864/4885 |
| US-20110092474-A1 | Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor | HRH4, HRH3, HRH2 | HRH4 1/4885HRH3 2/4885OGA 4873/4885 |
| US-20140357614-A1 | Diamino-Pyridine, Pyrimidine, and Pyrazine Modulators of the Histamine H4 Receptor | HRH4, HRH3, HRH2 | HRH4 1/4885HRH3 2/4885OGA 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.